未找到相关数据
Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial
被引：7
作者：
Hyman, D.
Piha-Paul, S.
Saura, C.
Arteaga, C.
Mayer, I.
Shapiro, G.
Loi, S.
Lalani, A.
Xu, F.
Cutler, R.
Butturini, A.
Bryce, R.
Meric-Bernstam, F.
Baselga, J.
Solit, D.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Vall Hebron Univ Hosp, VHIO, Barcelona, Spain
[4] Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[5] Dana Farber Canc Inst, Boston, MA 02215 USA
[6] Peter MacCallum Canc Inst, 481 Little Lonsdale St, Melbourne, Vic 3000, Australia
[7] Puma Biotechnol Inc, Los Angeles, CA USA
来源：
关键词：
D O I：
10.1158/1538-7445.SABCS16-PD2-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD2-08
引用
收藏
页数：2
相关论文